HomeAI · summaries
Storia in 3 fonti
Emcure buys remaining 12.05% in Gennova to take full control
Emcure Pharma is acquiring the remaining stake in Gennova Biopharmaceuticals. This move simplifies ownership and sharpens strategic focus for the subsidiary. Gennova will now be led by Samit Mehta for its next growth phase. The company will continue leveraging its biomanufacturing platforms for new products. Gennova's former CEO Sanjay Singh has divested its mRNA business.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Emcure subsidiary Gennova to transfer mRNA business to Immunoscript Life Science for ₹139 crore
Emcure's Gennova transfers its mRNA business to Immunoscript Life Science for ₹139 crore, focusing on core biotech operations.
- ·
Emcure consolidates stake in Gennova, under stewardship of promoter family scion
Gennova is a ₹49-crore company and it mRNA business, at ₹6.47 crore, represented 0.71% of consolidated revenue of the company of ₹911.58 crore, Emcure said
